Comparative Evaluation of Tigecycline and other Antimicrobials in the United States Against Multi-drug Resistant (MDR) Staphylococcus aureus

Abstract

Objectives: Worldwide methicillin-resistant S.aureus (MRSA) are increasing dramatically with corresponding resistance to multiple drug classes (MDR). Tigecycline, a new glycylcycline offers the potential of enhanced activity against MDR S. aureus. The tigecycline evaluation surveillance trial (T.E.S.T.) evaluated the activity of tigecycline and comparators to MDR S. aureus(including MR + MS strains) isolated in the United States. Methods: 193 hospital sites in the United States, between 2004 and 2007, collected 5280 clinically significant S. aureus. MICs were performed as specified by CLSI at each site. Results: MIC90 of tigecycline and comparators to S. aureus resistant groups 0–3+ are shown in the following table: Conclusions: Tigecycline demonstrated in vitro activity comparable to that of linezolid and vancomycin against all multidrug resistant groups of S. aureus. Tigecycline in vitro activity is unaffected by multidrug resistant phenotypes of S. aureus and offers an alternative in the treatment of infections due to S. aureus where approved indications apply.